ArticleVaccines2023

A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2.

Takenao Koseki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.